COLL Collegium Pharmaceutical, Inc. Common Stock
XNAS
24.87
Delayed
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
COLL
$24.87
—
What changed
Recent filings, trades and movesKey stats
$24.87
- 52-Week Range
- $21.43 – $50.79
- YTD
- -45.37%
- IV Rank (30D)
- 36.49
- Straddle Price
- $4.40
- P/C Vol Ratio
- 1.17
- Market Cap
- $0.8B
- Open
- $24.41
- Day Range
- $24.22 – $24.94
- Volume
- 318,392
- Prev Close
- $24.21
Fair Value
+50.0% vs price
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 4.90% |
| Beta vs SPY | 0.64 |
| Cost of Equity (CAPM) | 8.09% (VRP-adj) |
| WACC | 5.91% |
| Volatility Risk Premium | +64.5pp (IV − HV30) |
| Effective Tax Rate | 38.3% |
| Rev. Growth (YoY, DCF input) | -4.5% |
| DCF Horizon | 12 years explicit + fade |
| Free Cash Flow (TTM) | $0.3B |
| Return on Equity (TTM) | 15.4% |
| Book / Price | 39.7% — banking bias active (P/B is primary) |
| Gross Margin (TTM) | 74.7% |
| FCF Margin (TTM) | 40.6% |
| Debt / Equity | 3.32 |
| Quality Score | 4/6 — high quality (12y DCF) |
| SMA 50 | $22.99 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $23.29 |
| Bollinger Width / SMA20 | 13.0% (drives anchor stability) |
| Net Debt | $0.9B |
| Market Cap | $1B |
Peers used for multiples: BIIB, HRMY, OSCR, REGN
(filtered from 8 ETF-co-members; sector bias active)
Blended Fair Value
$74.97
Deviation
+50.0%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | $154.85 | 25% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | $28.03 | 11% | median 19.0× · 4 peers |
| Peer EV/EBITDA | $156.67 | 11% | median 15.3× · 4 peers |
| Peer P/B | $22.58 | 2% | median 2.4× · 4 peers |
| Peer P/S | $67.60 | 8% | median 2.7× · 4 peers |
| Market Anchor (SMA50) | $22.99 | 43% | stability 85% (BB-width) |
| Options Expected (B-L 30d) | $23.89 | 0% | 5 strikes · skew +0.17 |
As of 2026-11-09 · updated
Related
About
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834) · industry map
- Exchange
- XNAS
- Market Cap
- $0.8B
- Employees
- 423
- List Date
- 2015-05-07
- CIK
- 0001267565
- Last Earnings
- Nov 5 before open · +6.3% vs ±23.8% expected
- Next Earnings
- ~Feb 25, 2027 (estimated)
- Headquarters
- Stoughton, MA
- Homepage
- https://www.collegiumpharma.com
Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nu…
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | 21.55% | -6.50% | 19.08% | 5.54% | 12.19% | 0.86% | 8.79% |
| Feb | 2.39% | 7.93% | -9.52% | 9.68% | -6.89% | -11.55% | -1.33% |
| Mar | 3.36% | 9.99% | -10.45% | 4.55% | 4.96% | -20.50% | -1.35% |
| Apr | -4.62% | -18.40% | -1.77% | -5.02% | -8.15% | 1.44% | -6.09% |
| May | 3.91% | -2.25% | -4.00% | -12.28% | 7.69% | -2.07% | -1.50% |
| Jun | 3.23% | 14.47% | -3.85% | -0.22% | 0.89% | 13.91% | 4.74% |
| Jul | 3.75% | -5.34% | 6.21% | 18.24% | -1.45% | -2.57% | 3.14% |
| Aug | -17.75% | 3.41% | 2.85% | -0.34% | 29.03% | -30.83% | -2.27% |
| Sep | -1.91% | -9.49% | -5.86% | 3.26% | -10.65% | -9.08% | -5.62% |
| Oct | -1.65% | 11.15% | -4.39% | -14.01% | 2.36% | 8.97% | 0.41% |
| Nov | -14.74% | 17.90% | 17.57% | -8.85% | 29.31% | 5.03%* | 7.70% |
| Dec | 6.74% | 1.40% | 20.23% | -8.55% | -1.20% | -- | 3.72% |
| Total | -1.40% | 19.31% | 21.58% | -12.25% | 62.57% | -43.72% | 7.68% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $23.43
SMA 50: $22.98
SMA 200: $32.57
Current: $24.87
EMA 12: $23.93
EMA 26: $23.57
MACD: 0.3595 | Signal: 0.2184
BULLISH
ADX (14): 23.25
WEAK TREND
+DI: 30.68
−DI: 15.48
Momentum Oscillators
RSI (14): 61.46
NEUTRAL
Stoch %K: 61.23
Stoch %D: 63.42
Williams %R: -35.86
Volume & Volatility
BB Upper: $24.98
BB Lower: $21.89
NEUTRAL
OBV: 15,755,640
Vol SMA 20: 676,504
Vol ROC: -38.65%
ATR: $0.98
True Range: $0.73
HV 20: 39.4%
HV 30: 33.6%
HV 60: 32.5%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-11-08T00:00:00 – 2026-11-06T00:00:00
AI Analysis
Written before COLL’s Nov 5 earnings report, so it doesn’t reflect the results.
LLM Stock Analysis Report
Executive Summary
This report provides a comprehensive analysis of Collegium Pharmaceutical (COLL) stock, incorporating technical indicators, options metrics, beta analysis, market data, and recent news headlines.
Overall Assessment: NEUTRAL with confidence level 6/10. Key drivers include the company's acquisition of AZSTARYS and positive news sentiment from recent headlines. Primary risks include the potential impact of regulatory changes on the ADHD treatment landscape and volatility in the options market.
Investment Thesis: COLL is a mid-cap pharmaceutical company with a strong track record of growth, driven by its innovative ADHD treatments. While the stock has exhibited low volatility, it may be influenced by upcoming catalysts such as earnings releases and product launches.
Recent News Sentiment Impact: The majority of recent headlines have been positive, highlighting the company's acquisition of AZSTARYS and participation in conferences. However, some neutral news articles discussing general market commentary have also been reported.
Technical Analysis
Trend Direction: Short-term (1-4 weeks): NEUTRAL, Medium-term (1-3 months): BEARISH, Long-term (3-12 months): BULLISH
Support/Resistance Levels: Key price levels from moving averages:
- SMA 20: $32.47
- SMA 50: $34.12
- SMA 200: $39.08
Momentum Signals:
- RSI interpretation: Neutral (33.31)
- MACD signal: Bearish (-2.16 / Signal: -0.64 / Histogram: -1.52)
Volume Analysis: Volume trends and institutional interest signals:
- Volume SMA 20: 663665.70
- On-Balance Volume (OBV): 18006513.16
- Volume Rate of Change: 131.08%
News & Sentiment Analysis
Recent Headlines Summary: Key themes from last 10 news articles: Acquisition, product launches, and conference participation.
Sentiment Assessment: Aggregate news sentiment: POSITIVE with a confidence level of 7/10.
Catalyst Identification: Upcoming events:
- Earnings releases
- Product launches
- Regulatory changes
Market Narrative: News aligns with technical signals indicating a potential uptrend.
Risk & Volatility Assessment
Beta Interpretation: Risk relative to market: Low (0.32)
Volatility Regime: Current vs historical volatility levels: Low volatility - stock moves less than market.
Options Market Signals: IV rank, put/call ratios:
- IV Rank: 51.8% (Medium)
- Put/Call Volume Ratio: 1.06 (Neutral sentiment)
- Put/Call OI Ratio: 0.45
Market Context & Positioning
Sector Performance: Relative strength vs sector/market: Strong within the pharmaceutical sector.
Institutional Activity: Volume patterns suggesting institutional interest:
- Institutional buying pressure
- High volume at key price levels
Correlation Analysis: How stock moves relative to market (R-squared interpretation): Correlated with the market (0.09).
Key Levels & Action Items
Critical Price Levels: Support/resistance to monitor:
- SMA 20: $32.47
- SMA 50: $34.12
- SMA 200: $39.08
Breakout/Breakdown Levels: Technical levels that could trigger significant moves:
- Lower band Bollinger Bands: $24.56
- Upper band Bollinger Bands: $40.38
Time-Sensitive Catalysts: Earnings dates, FDA approvals, product launches:
- Upcoming earnings release (no specific date available)
Risk Management: Stop-loss levels and position sizing considerations:
- Set stop-loss at SMA 20 ($32.47)
- Consider scaling into the trade with a larger position size
Overall, this report provides a comprehensive analysis of Collegium Pharmaceutical's stock, highlighting both technical and fundamental factors that may influence its performance.
Generated
News
All COLL news →
Jornay PM growth outpaced a steep pain-segment drop this quarter.
Earnings History
17 of 19 under expected move
Avg Expected Move
13.00%
Avg Actual Move
5.71%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2021-02-25 | After-Close | 11.45% | 9.37% | 0.82x | Within |
| 2021-05-06 | After-Close | 3.65% | 4.83% | 1.32x | Exceeded |
| 2021-11-04 | After-Close | 7.13% | 1.50% | 0.21x | Within |
| 2022-05-10 | After-Close | 10.91% | 0.14% | 0.01x | Within |
| 2023-05-04 | After-Close | 12.88% | 3.20% | 0.25x | Within |
| 2023-08-03 | After-Close | 13.53% | 6.68% | 0.49x | Within |
| 2023-11-07 | After-Close | 15.36% | 6.60% | 0.43x | Within |
| 2024-02-22 | After-Close | 17.37% | 10.79% | 0.62x | Within |
| 2024-05-09 | After-Close | 14.03% | 16.80% | 1.20x | Exceeded |
| 2024-08-08 | Pre-Market | 14.57% | 1.93% | 0.13x | Within |
| 2024-11-07 | After-Close | 10.66% | 7.35% | 0.69x | Within |
| 2025-02-27 | After-Close | 19.00% | 2.22% | 0.12x | Within |
| 2025-05-08 | After-Close | 15.40% | 5.94% | 0.39x | Within |
| 2025-08-07 | After-Close | 7.89% | 6.04% | 0.77x | Within |
| 2025-11-06 | After-Close | 9.22% | 4.03% | 0.44x | Within |
| 2026-02-26 | After-Close | 10.69% | 5.77% | 0.54x | Within |
| 2026-05-07 | Pre-Market | 14.45% | 7.72% | 0.53x | Within |
| 2026-08-06 | After-Close | 15.03% | 1.24% | 0.08x | Within |
| 2026-11-05 | Pre-Market | 23.76% | 6.29% | 0.26x | Within |
Earnings calendar: this week’s reports with expected vs actual moves →
COLL Options Activity & IV Rank
COLL IV rank history, 52-week IV rank and IV percentile →
Volatility Metrics
Current IV: 71.7%
7-DTE IV: 72.6%
Expected Move: $4.40
7-DTE Move: $4.15
Days to Exp: 39 (2026-12-18)
Options Flow · All expiries
Call Volume: 75
Put Volume: 88
P/C Volume: 1.173
NEUTRAL
Call OI: 472
Put OI: 276
P/C OI: 0.585
Total OI: 748
ATM Options Pricing
ATM Call: $2.20
ATM Put: $2.20
Call %: 8.8%
Put %: 8.8%
Chain Summary
Chain Volume: 163
Chain OI: 748
Last Updated: 11/9/2026
Spread Scanner
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Calendars: the long leg is valued at the short leg’s expiration (Black-Scholes at its current IV) across the range of prices the short leg’s IV implies, giving the best-case profit (R/R = that over the debit) and P(profit).
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Scanning bull put, bear call, iron condor and calendar spreads…
Dealer Positioning
TYPICAL γ
Estimated net dealer gamma is at the 57th percentile of this name's own daily history, within its typical range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
57%
vs own history
GEX tilt
+0.87
OI-weighted, today
Vanna tilt
+0.09
δ-sensitivity to IV
Charm tilt
-0.61
δ-decay vs time
Charm tilt -0.61: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably as time passes and options approach expiry.
? What is this?
· 5 ATM contracts, 0k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
No data
30 DTE / 10d
—
—
pts
EXTREME
No data
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Loading the implied volatility surface…
Volatility Smile
Loading the implied volatility smile…
IV Rank (7 DTE)17.7LowNov 9
IV Rank (30 DTE)36.5MediumNov 9
Straddle Price (30 DTE)$4.40Nov 9
Beta Analysis
Risk Metrics
Beta: 0.2115
Alpha: -46.78%
Correlation: 0.0688
R-Squared: 0.5%
Stock Volatility: 42.3%
Market Volatility: 13.8%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
Low volatility - stock moves less than market
Low volatility - stock moves less than market
Beta & Alpha Over Time
Notable investors who own COLL
5 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Renaissance Technologies Hedge fund Jim Simons | $49.5M | #334 of 3138 | -7.0% | 13F | |
| Millennium Management Hedge fund Izzy Englander | $26.7M | #953 of 3716 | +104.2% | 13F | |
| Point72 Hedge fund Steve Cohen | $4.1M | #1040 of 1945 | new | 13F | |
| Citadel Hedge fund Ken Griffin | $2.5M | #2702 of 6285 | -43.5% | 13F | |
| Rockefeller Capital Management Family office Rockefeller family | $2K | #4401 of 4729 | -59.5% | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
COLL Institutional Ownership (13F)
Filings for 2026-06-30 · 90 already for 2026-09-30
? 13F Guide
Diluted shares outstanding: 37,917,007 (as of 2026-06-30)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
3 filers$1.80M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $1.35M | 75.01% | 2026-06-30 |
| 2 | Jane Street Group, LLC Custodian | $448.88K | 24.87% | 2026-06-30 |
| 3 | Simplex Trading, LLC Custodian | $2.18K | 0.12% | 2026-09-30 |
3 filers$3.84M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $2.71M | 70.43% | 2026-06-30 |
| 2 | Citadel Advisors LLC Custodian | $731.24K | 19.02% | 2026-06-30 |
| 3 | Simplex Trading, LLC Custodian | $405.85K | 10.56% | 2026-09-30 |
COLL Insider Trading (Form 4)
Latest: 2026-06-10Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-06-10 | Gino Santini | Director | Exer (M) | +8,700 | $16.49 | $143.5K | EDGAR |
| 2026-05-20 | John Gordon Freund | Director | Sell (S) | −20 | $34.05 | -$681 | EDGAR |
| 2026-05-18 | Garen G Bohlin | Director | Award (A) | +8,741 | — | EDGAR | |
| 2026-05-18 | Carlos V Paya | Director | Award (A) | +8,741 | — | EDGAR | |
| 2026-05-18 | Donovan Michael Glancy | Director | Award (A) | +17,482 | — | EDGAR | |
| 2026-05-18 | Gino Santini | Director | Award (A) | +8,741 | — | EDGAR | |
| 2026-05-18 | Rita J. Balice-Gordon | Director | Award (A) | +8,741 | — | EDGAR | |
| 2026-05-18 | Nancy Lurker | Director | Award (A) | +8,741 | — | EDGAR | |
| 2026-05-18 | John Gordon Freund | Director | Mixed Grant +8,741 · Exer +8,700 · Sell −4,127 |
+13,314 | $22.30 | $916 | EDGAR |
| 2026-05-15 | Nancy Lurker | Director | Sell (S) | −4,500 | $35.97 | -$161.9K | EDGAR |
| 2026-05-13 | Garen G Bohlin | Director | Mixed Exer +8,700 · Sell −8,700 |
— | $26.84 | -$180.0K | EDGAR |
| 2026-04-03 | David Dieter | EVP & General Counsel | Tax (F) | −8,840 | $35.72 | -$315.8K | EDGAR |
| 2026-03-20 | David Dieter | EVP & General Counsel | Sell (S) | −13,976 | $34.92 | -$488.1K | EDGAR |
| 2026-03-11 | David Dieter | EVP & General Counsel | Sell (S) | −6,224 | $36.65 | -$228.1K | EDGAR |
| 2026-03-05 | Scott Dreyer | EVP & Chief Commercial Officer | Sell (S) | −49,976 | $40.41 | -$2.02M | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
COLL Insider Holdings
16 insiders · @ $24.87
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Rubric Capital Management LP | 10%+ Owner | 3,132,743 | $77.91M | -$946.2K | 1 | 2025-08-15 |
| 2 | Michael Thomas Heffernan | Director | 213,371 | $5.31M | -$15.14M | 17 | 2025-02-12 |
| 3 | Vikram Karnani | President and CEO | 209,160 | $5.20M | $0 | 3 | 2026-02-12 |
| 4 | Colleen Tupper | EVP & Chief Financial Officer | 185,822 | $4.62M | -$3.39M | 15 | 2026-02-12 |
| 5 | Shirley R. Kuhlmann | EVP and General Counsel | 134,204 | $3.34M | -$7.87M | 24 | 2025-03-06 |
| 6 | Gino Santini | Director | 112,483 | $2.80M | -$201.0K | 10 | 2026-06-10 |
| 7 | John Gordon Freund | Director | 107,081 | $2.66M | $1.05M | 14 | 2026-05-20 |
| 8 | John A. Fallon | Director | 99,487 | $2.47M | -$1.65M | 7 | 2025-11-14 |
| 9 | Thomas B Smith | EVP and Chief Medical Officer | 90,651 | $2.25M | -$1.06M | 7 | 2026-02-12 |
| 10 | Scott Dreyer | EVP & Chief Commercial Officer | 75,329 | $1.87M | -$12.01M | 36 | 2026-03-05 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
COLL Board & Officers
As of SEC filings through Jun 10, 2026Directors 8
- Garen G Bohlin · since May 6, 2015
- Gino Santini · since May 6, 2015
- John Gordon Freund · since May 6, 2015
- Rita J. Balice-Gordon · since Sep 24, 2020
- Vikram Karnani · since Nov 12, 2024
- Nancy Lurker · since Feb 4, 2025
- Carlos V Paya · since May 15, 2025
- Donovan Michael Glancy · since May 14, 2026
Officers 4
- Vikram Karnani · President and CEO · since Nov 12, 2024
- Colleen Tupper · EVP & Chief Financial Officer · since May 24, 2021
- Scott Dreyer · EVP & Chief Commercial Officer · since Jul 10, 2018
- David Dieter · EVP & General Counsel · since Mar 17, 2025
Changes in the last 10 years (41)
| May 14, 2026 | Donovan Michael Glancy became a director |
| May 11, 2026 | The company announced the departure of Thomas B Smith as EVP and Chief Medical Officer in an SEC filing |
| Apr 2, 2026 | The company announced the departure of John A. Fallon from the board in an SEC filing |
| Aug 15, 2025 | Rubric Capital Management LP reported in an SEC filing no longer being a 10% owner |
| Aug 15, 2025 | David Efraim Rosen reported in an SEC filing no longer being a 10% owner |
| Aug 7, 2025 | Rubric Capital Management LP became a 10% owner |
| Aug 7, 2025 | David Efraim Rosen became a 10% owner |
| May 15, 2025 | Carlos V Paya became a director |
| Mar 17, 2025 | David Dieter became EVP & General Counsel |
| Mar 11, 2025 | The company announced the departure of Gwen A Melincoff from the board in an SEC filing |
| Mar 6, 2025 | Shirley R. Kuhlmann reported in an SEC filing no longer being EVP and General Counsel |
| Feb 4, 2025 | Nancy Lurker became a director |
| Nov 12, 2024 | Vikram Karnani became a director |
| Nov 12, 2024 | Vikram Karnani became President and CEO |
| Jul 28, 2024 | The company announced the departure of Neil F. McFarlane from the board in an SEC filing |
| May 24, 2024 | The company announced the departure of Michael Thomas Heffernan from the board in an SEC filing |
| May 24, 2024 | The company announced the departure of Michael Thomas Heffernan as Chairman, President and CEO in an SEC filing |
| May 9, 2024 | The company announced the departure of Joseph Ciaffoni from the board in an SEC filing |
| May 9, 2024 | The company announced the departure of Joseph Ciaffoni as President and CEO in an SEC filing |
| Apr 6, 2022 | Neil F. McFarlane became a director |
| Mar 23, 2022 | Thomas B Smith became EVP and Chief Medical Officer |
| Mar 22, 2022 | The company announced the departure of Richard Malamut as EVP and Chief Medical Officer in an SEC filing |
| May 24, 2021 | Colleen Tupper became EVP & Chief Financial Officer |
| Apr 5, 2021 | Alison B Fleming listed as EVP & Chief Technical Officer (previously Chief Technical Officer) in SEC filings |
| Feb 12, 2021 | Alison B Fleming listed as Chief Technical Officer (previously Chief Technology Officer) in SEC filings |
| Sep 24, 2020 | Rita J. Balice-Gordon became a director |
| Apr 1, 2019 | Richard Malamut became EVP and Chief Medical Officer |
| Jul 10, 2018 | Scott Dreyer became EVP & Chief Commercial Officer |
| Jul 2, 2018 | Joseph Ciaffoni listed as President and CEO (previously Chief Operating Officer) in SEC filings |
| Jul 2, 2018 | Joseph Ciaffoni first listed as a director in an SEC filing |
| May 29, 2018 | David Hirsch no longer listed as a 10% owner in SEC filings |
| Mar 21, 2018 | John Gordon Freund no longer listed as a 10% owner in SEC filings |
| Mar 16, 2018 | Shirley R. Kuhlmann became EVP and General Counsel |
| Dec 12, 2017 | Patrick G Enright reported in an SEC filing no longer being a 10% owner |
| Dec 12, 2017 | Longitude Venture Partners L.P. reported in an SEC filing no longer being a 10% owner |
| Dec 12, 2017 | Longitude Capital Partners, LLC reported in an SEC filing no longer being a 10% owner |
| Dec 12, 2017 | Longitude Capital Associates, L.P. reported in an SEC filing no longer being a 10% owner |
| Dec 12, 2017 | Bakker Juliet Tammenoms reported in an SEC filing no longer being a 10% owner |
| Aug 9, 2017 | Gwen A Melincoff became a director |
| May 31, 2017 | Joseph Ciaffoni became Chief Operating Officer |
| Feb 14, 2017 | Alison B Fleming listed as Chief Technology Officer (previously Vice President, Product Devlp) in SEC filings |
Not reported recently (8)
- Alison B Fleming · Last reported as EVP & Chief Technical Officer in an SEC filing dated Aug 12, 2021
- Paul Brannelly · Last reported as Executive Vice President & CFO in an SEC filing dated Feb 12, 2021
- David Hirsch · Last reported as a director in an SEC filing dated May 22, 2020
- Theodore R Schroeder · Last reported as a director in an SEC filing dated May 22, 2020
- Skyline Venture Partners V LP · Last reported as a 10% owner in an SEC filing dated Dec 7, 2017
- Skyline Venture Management V, LLC · Last reported as a 10% owner in an SEC filing dated Dec 7, 2017
- Yasunori Kaneko · Last reported as a 10% owner in an SEC filing dated Dec 7, 2017
- Barry S Duke · Last reported as Executive Vice President and Chief Commercial Officer in an SEC filing dated Mar 21, 2017
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
COLL Proposed Insider Sales (Form 144)
Latest: 2026-09-30
? Form 144 Guide
Last 30d:
0 filings
· Last 90d:
1 filing
· $603K notice value
· 1 unique filer
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
Top 90-day filers:
Dreyer Scott (1, $603K)
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2026-09-30 | Dreyer Scott | Former Officer | 27,419 | $603.3K | 2026-09-30 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2026-07-17 | Fallon John A. | Former Director | 13,920 | $497.4K | 2026-07-17 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2026-07-15 | Fallon John A. | Former Director | 8,095 | $294.0K | 2026-07-15 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2026-05-18 | Freund John Gordon | Director | 30 | $1.0K | 2026-05-18 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2026-05-15 | Freund John Gordon | Director | 4,127 | $142.5K | 2026-05-15 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2026-05-13 | Lurker Nancy | Director | 4,500 | $161.9K | 2026-05-13 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2026-05-11 | BOHLIN GAREN G | Director | 8,700 | $323.5K | 2026-05-11 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2026-03-18 | Dieter David | Officer | 13,976 | $488.1K | 2026-03-18 | Fidelity Brokerage Services LLC | 10b5-1 | EDGAR |
| 2026-03-09 | Dieter David | Officer | 6,224 | $228.1K | 2026-03-09 | Fidelity Brokerage Services LLC | 10b5-1 | EDGAR |
| 2026-03-03 | Dreyer Scott | Officer | 49,976 | $2.02M | 2026-03-03 | Fidelity Brokerage Services LLC | 10b5-1 | EDGAR |
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
Recent SEC Filings
Latest: 2026-11-05
Current reports — material events the company must disclose within 4 business days (earnings releases, M&A, executive changes, etc.).
Annual report — audited financial statements, MD&A, risk factors. Filed 60–90 days after fiscal year-end.
| Filing Date | Accession | Link |
|---|
ETF Holders
105 ETFs hold COLL
25 shown · $229.99M total exposure · 0.05% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | IJR iShares Core S&P Small-Cap ETF | iShares (BlackRock) | 0.05% | $47.6M | $103.8B | 2026-11-06 |
| 2 | VTI Vanguard Morningstar Total Stock Market ETF | Vanguard | 0.00% | $21.3M | — | 2026-09-30 |
| 3 | IWM iShares Russell 2000 ETF | iShares (BlackRock) | 0.03% | $20.9M | $76.6B | 2026-11-06 |
| 4 | PJP Invesco Pharmaceuticals ETF | Invesco | 2.86% | $16.6M | — | 2026-11-05 |
| 5 | AVUV Avantis U.S. Small Cap Value ETF | Avantis | 0.04% | $12.2M | $31.6B | 2026-11-05 |
| 6 | PBE Invesco Biotechnology & Genome ETF | Invesco | 2.48% | $10.7M | — | 2026-11-05 |
| 7 | XPH State Street® SPDR® S&P® Pharmaceuticals ETF | SPDR (State Street) | 2.23% | $10.4M | $466.5M | 2026-11-05 |
| 8 | CALF Pacer US Small Cap Cash Cows 100 ETF | Nport | 0.26% | $9.6M | — | 2026-07-31 |
| 9 | VXF Vanguard Extended Market ETF | Vanguard | 0.01% | $8.0M | — | 2026-09-30 |
| 10 | SPSM State Street® SPDR® Portfolio S&P 600™ Small Cap ETF | SPDR (State Street) | 0.05% | $7.5M | $15.7B | 2026-11-05 |
| 11 | IWO iShares Russell 2000 Growth ETF | iShares (BlackRock) | 0.05% | $7.5M | $13.7B | 2026-11-06 |
| 12 | IJT iShares S&P Small-Cap 600 Growth ETF | iShares (BlackRock) | 0.10% | $7.1M | $7.3B | 2026-11-06 |
| 13 | DFAS Dimensional US Small Cap ETF | Dimensional | 0.02% | $6.6M | — | 2026-11-05 |
| 14 | USVM VictoryShares US Small Mid Cap Value Momentum ETF | Nport | 0.33% | $5.7M | — | 2026-06-30 |
| 15 | SFLO VictoryShares Small Cap Free Cash Flow ETF | Nport | 0.79% | $4.8M | — | 2026-06-30 |
| 16 | SLYG State Street® SPDR® S&P 600™ Small Cap Growth ETF | SPDR (State Street) | 0.10% | $4.6M | $4.6B | 2026-11-05 |
| 17 | DFAT Dimensional US Targeted Value ETF | Dimensional | 0.01% | $4.3M | — | 2026-11-05 |
| 18 | VTWO Vanguard Russell 2000 ETF | Vanguard | 0.02% | $4.2M | — | 2026-09-30 |
| 19 | SCHA Schwab U.S. Small-Cap ETF | Nport | 0.02% | $3.8M | — | 2026-08-31 |
| 20 | DFAC Dimensional US Core Equity 2 ETF | Dimensional | 0.00% | $3.1M | — | 2026-11-05 |
| 21 | DFMC Dimensional US Micro Cap ETF | Dimensional | 0.04% | $3.0M | — | 2026-11-05 |
| 22 | MGMT BALLAST SMALL/MID CAP ETF | Nport | 1.59% | $2.8M | — | 2026-06-30 |
| 23 | IHE iShares U.S. Pharmaceuticals ETF | iShares (BlackRock) | 0.17% | $2.7M | $1.7B | 2026-11-06 |
| 24 | VIOO Vanguard S&P Small-Cap 600 ETF | Vanguard | 0.04% | $2.5M | — | 2026-09-30 |
| 25 | FNDA Schwab Fundamental U.S. Small Company ETF | Nport | 0.03% | $2.5M | — | 2026-08-31 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
20.22
TTM Diluted EPS
$1.23
TTM Revenue
$808.21M
TTM Net Income
$47.91M
TTM Op. Cash Flow
$329.92M
Quarterly figures (12 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q2 '26 | 2026-06-30 | $199.88M | $-15.05M | $-0.46 | $71.32M |
| Q1 '26 | 2026-03-31 | $193.52M | $14.50M | $0.40 | $57.11M |
| Q4 '25 | 2025-12-31 | $205.45M | $16.96M | $0.45 | $123.05M |
| Q3 '25 | 2025-09-30 | $209.36M | $31.51M | $0.84 | $78.44M |
| Q2 '25 | 2025-06-30 | $188.00M | $11.98M | $0.34 | $72.44M |
| Q1 '25 | 2025-03-31 | $177.76M | $2.42M | $0.07 | $55.40M |
| Q4 '24 | 2024-12-31 | $181.95M | $12.54M | $0.35 | $84.64M |
| Q3 '24 | 2024-09-30 | $159.30M | $9.34M | $0.27 | $-9.00M |
| Q2 '24 | 2024-06-30 | $145.28M | $19.61M | $0.52 | $67.40M |
| Q1 '24 | 2024-03-31 | $144.92M | $27.71M | $0.71 | $61.94M |
| Q4 '23 | 2023-12-31 | $149.75M | $31.94M | $0.82 | $73.34M |
| Q3 '23 | 2023-09-30 | $136.71M | $20.63M | $0.53 | $74.02M |
Q2 2026 • period ending 2026-06-30 • filed 2026-08-06
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
20.22
P/B
3.02
P/S
1.17
EV/EBITDA
4.72
EV/Sales
2.29
ROE
15.4%
ROA
2.2%
Div Yield
0.00%
FCF Yield
34.99%
Debt/Equity
3.32
Current Ratio
—
Market Cap
$943.00M
as of 2026-11-09
COLL vs Peers
Related companies, largest first| Company | Market cap | P/E | Revenue growth | YTD | IV rank |
|---|---|---|---|---|---|
| LLY Eli Lilly & Co. | $1.21T | 46.0 | +45.5% | +31.3% | 27 |
| JNJ Johnson & Johnson | $664.9B | 42.9 | +7.8% | +36.2% | 58 |
| AMGN Amgen Inc | $249.0B | 27.0 | +8.2% | +42.0% | 34 |
| GILD Gilead Sciences Inc | $207.0B | — | +6.5% | +39.5% | 56 |
| REGN Regeneron Pharmaceuticals Inc | $93.6B | 20.5 | +18.6% | +19.6% | 58 |
| BIIB Biogen Inc. Common Stock | $36.7B | 110.3 | +2.3% | +45.2% | 100 |
| OSCR Oscar Health, Inc. | $9.5B | — | +32.3% | +110.8% | 0 |
| HRMY Harmony Biosciences Holdings, Inc. Commo | $1.9B | 11.2 | +19.8% | −9.6% | 44 |
| COLL Collegium Pharmaceutical, Inc. Common St | $752M | 20.2 | +14.3% | −45.4% | 36 |
| Peer median | $150.3B | 35.0 | +13.4% | +37.9% | 50 |
P/E uses the latest reported trailing-12-month diluted EPS; "—" means no positive earnings or no data.
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
5.38M
SI % of Float
17.57%
Days to Cover
7.17
Short Vol Ratio
44.1%
Free Float
30.60M
Float %
94.0%
Short interest 2026-10-15 • Short volume 2026-11-06 • Float 2026-10-08